Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: a national Veterans Administration study.

[1]  A. Shroyer,et al.  Prescription-filling rates for key medications in Veterans Affairs patients after coronary artery bypass grafting. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[2]  C. Gullion,et al.  Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. , 2004, Journal of the American Society of Nephrology : JASN.

[3]  J. Herlitz.  Secondary prevention after coronary artery bypass grafting – what do we know? , 2004, Scandinavian cardiovascular journal : SCJ.

[4]  L. Szczech,et al.  Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  G. Bakris,et al.  Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients? , 2003, American Journal of Kidney Diseases.

[6]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[7]  H. Krumholz,et al.  Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. , 2003, Journal of the American College of Cardiology.

[8]  S. Seliger,et al.  Editorials: Are HMG‐CoA Reductase Inhibitors Underutilized in Dialysis Patients? , 2003, Seminars in dialysis.

[9]  P. Golino,et al.  Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. , 2003, Journal of the American College of Cardiology.

[10]  M. Pfeffer,et al.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy , 2003, Annals of Internal Medicine.

[11]  K. Eagle,et al.  Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. , 2003, Journal of the American College of Cardiology.

[12]  Eugene Crystal,et al.  Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the beta-Blocker Length Of Stay (BLOS) study. , 2003, American heart journal.

[13]  M. Mcclellan,et al.  Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients , 2002, Annals of Internal Medicine.

[14]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[15]  B. McNeil,et al.  Understanding Individual and Small Area Variation in the Underuse of Coronary Angiography Following Acute Myocardial Infarction , 2002, Medical care.

[16]  E. Lewis,et al.  Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes , 2002 .

[17]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[18]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[19]  I. Holme,et al.  Effects of Fluvastatin on Cardiac Events in Renal Transplant Patients: ALERT (Assessment of Lescol® in Renal Transplantation) Study Design and Baseline Data , 2001, Journal of cardiovascular risk.

[20]  B. Hoogwerf,et al.  Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial , 2000 .

[21]  C. Roberts.  Postoperative drug therapy to extend survival after coronary artery bypass grafting. , 2000, The Annals of thoracic surgery.

[22]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[23]  Thomas E. Moritz,et al.  Health-Related Quality of Life As a Predictor of Mortality Following Coronary Artery Bypass Graft Surgery , 1999, Survey of Anesthesiology.

[24]  D. Bello,et al.  Self-reported differences between cardiologists and heart failure specialists in the management of chronic heart failure. , 1999, American heart journal.

[25]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[26]  Robert J. Anderson,et al.  Clinical Nephrology – Epidemiology – Clinical TrialsRenal failure predisposes patients to adverse outcome after coronary artery bypass surgery , 1999 .

[27]  Thomas E. Moritz,et al.  Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery , 1999 .

[28]  E. Philbin,et al.  Angiotensin‐Converting Enzyme Inhibitor Use in Older Patients with Heart Failure and Renal Dysfunction , 1999, Journal of the American Geriatrics Society.

[29]  M. Pfeffer,et al.  Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  E. Philbin.  Factors determining angiotensin‐converting enzyme inhibitor underutilization in heart failure in a community setting , 1998, Clinical cardiology.

[31]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[32]  J. Copeland,et al.  Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. , 1989, Circulation.

[33]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[34]  F. Ruddle,et al.  Report of the committee on the genetic constitution of autosomes other than chromosomes 1,2 and 6. , 1976, Birth defects original article series.